Targeting Aurora kinase A and JAK2 prevents GVHD while maintaining Tregand antitumor CTL function

Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host disease

(2015) J. Pidala et al.   HAEMATOLOGICA

The Energy Sensor AMPK Regulates T Cell Metabolic Adaptation and Effector Responses In Vivo

(2015) Julianna Blagih et al.   IMMUNITY

CD4+ T cell STAT3 phosphorylation precedes acute GVHD, and subsequent Th17 tissue invasion correlates with GVHD severity and therapeutic response

(2015) Brian C. Betts et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Immunosuppressive human anti-CD83 monoclonal antibody depletion of activated dendritic cells in transplantation

(2015) T A Seldon et al.   LEUKEMIA

Selective NFAT targeting in T cells ameliorates GvHD while maintaining antitumor activity

(2015) Martin Vaeth et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Low expression of CD39 on regulatory T cells as a biomarker for resistance to methotrexate therapy in rheumatoid arthritis

(2015) Raphael Sanches Peres et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Transcriptome analysis of GVHD reveals aurora kinase A as a targetable pathway for disease prevention

(2015) Scott N. Furlan et al.   Science Translational Medicine

Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host disease

(2015) J. Pidala et al.   HAEMATOLOGICA

A Cell Biologist’s Field Guide to Aurora Kinase Inhibitors

(2015) Christian O. de Groot et al.   Frontiers in Oncology

Dual Aurora A and JAK2 kinase blockade effectively suppresses malignant transformation

(2015) Hua Yang et al.   Oncotarget

Superiority of Rapamycin Over Tacrolimus in Preserving Nonhuman Primate Treg Half-Life and Phenotype After Adoptive Transfer

(2014) K. Singh et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT

(2014) C. Cutler et al.   BLOOD

Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS

(2014) C. G. Kanakry et al.   BLOOD

Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease

(2014) S. Spoerl et al.   BLOOD

Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial

(2014) Glen A Kennedy et al.   LANCET ONCOLOGY

Pharmacologic Blockade of JAK1/JAK2 Reduces GvHD and Preserves the Graft-Versus-Leukemia Effect

(2014) Jaebok Choi et al.   PLoS One

The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo

(2013) A. Heine et al.   BLOOD

Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis?

(2013) A. Heine et al.   BLOOD

STAT5 polarization promotes iTregs and suppresses human T-cell alloresponses while preserving CTL capacity

(2013) Brian C. Betts et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Interleukin-6 Receptor Blockade Enhances CD39+ Regulatory T Cell Development in Rheumatoid Arthritis and in Experimental Arthritis

(2013) A. Thiolat et al.   Arthritis & Rheumatology

Depletion of T regulatory cells through selection of CD127-positive cells results in a population enriched in memory T cells: implications for anti-tumor cell therapy

(2012) S. Touil et al.   HAEMATOLOGICA

A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation

(2012) J. Pidala et al.   HAEMATOLOGICA

STAT3 Transcription Factor Promotes Instability of nTreg Cells and Limits Generation of iTreg Cells during Acute Murine Graft-versus-Host Disease

(2012) Arian Laurence et al.   IMMUNITY

Comparative Outcomes of Donor Graft CD34+Selection and Immune Suppressive Therapy As Graft-Versus-Host Disease Prophylaxis for Patients With Acute Myeloid Leukemia in Complete Remission Undergoing HLA-Matched Sibling Allogeneic Hematopoietic Cell Transplantation

(2012) Marcelo C. Pasquini et al.   JOURNAL OF CLINICAL ONCOLOGY

IL-7 Abrogates Suppressive Activity of Human CD4+CD25+FOXP3+ Regulatory T Cells and Allows Expansion of Alloreactive and Autoreactive T Cells

(2012) A.-K. Heninger et al.   JOURNAL OF IMMUNOLOGY

Development of o-Chlorophenyl Substituted Pyrimidines as Exceptionally Potent Aurora Kinase Inhibitors

(2012) Harshani R. Lawrence et al.   JOURNAL OF MEDICINAL CHEMISTRY

Anti-IL6-receptor-alpha (tocilizumab) does not inhibit human monocyte-derived dendritic cell maturation or alloreactive T-cell responses

(2011) B. C. Betts et al.   BLOOD

Janus kinase-2 inhibition induces durable tolerance to alloantigen by human dendritic cell-stimulated T cells yet preserves immunity to recall antigen

(2011) B. C. Betts et al.   BLOOD

Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation

(2011) L Johnston et al.   BONE MARROW TRANSPLANTATION

Characterization of Alisertib (MLN8237), an Investigational Small-Molecule Inhibitor of Aurora A Kinase Using Novel In Vivo Pharmacodynamic Assays

(2011) M. G. Manfredi et al.   CLINICAL CANCER RESEARCH

Functional characterization of alloreactive T cells identifies CD25 and CD71 as optimal targets for a clinically applicable allodepletion strategy

(2009) S. Samarasinghe et al.   BLOOD

Generation and Accumulation of Immunosuppressive Adenosine by Human CD4+CD25highFOXP3+Regulatory T Cells

(2009) Magis Mandapathil et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Antibody to the dendritic cell surface activation antigen CD83 prevents acute graft-versus-host disease

(2009) John Wilson et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Efficacy of TG101348, a Selective JAK2 Inhibitor, in Treatment of a Murine Model of JAK2V617F-Induced Polycythemia Vera

(2008) Gerlinde Wernig et al.   CANCER CELL